Britain's long-delayed CBD food regime has reached a significant turning point.
On 3 September, the Food Standards Agency published recommendations supporting the first three high-purity CBD novel-food applications for authorisation by ministers in England and Wales. Food Standards Scotland has considered the same applications separately, while Northern Ireland operates within its own regulatory arrangements.
If ministers agree, this would be the first time CBD novel foods have completed the domestic authorisation process in Great Britain.
That is meaningful progress after years of uncertainty. It is not, however, a blanket approval for the CBD market. It does not turn a food supplement into a medicine, validate health claims or confirm that every bottle currently on a shelf is authorised.
What has been recommended
The three applications are known as RP 7, RP 350 and RP 427. They cover synthetic CBD and CBD isolates with purity of at least 98%.
The FSA says the products were found to be safe under the proposed conditions of use following assessments by the Advisory Committee on Novel Foods and Processes. They are intended for adults, with a maximum intake of 10 milligrams of CBD per day.
The recommendations include strict specifications for delta-9-THC and other controlled cannabinoids, together with mandatory safety information. Proposed labels would state the provisional acceptable daily intake and warn against use by under-18s; people who are pregnant, breastfeeding or trying to conceive; people taking medication; and people who are immunosuppressed.
The FSA received 46 responses to its consultation. It reports that 68% supported the overall risk-management proposals, although respondents asked for clearer explanations and some targeted changes.
The board paper recommends that officials now send the applications to ministers. Ministers, not the FSA board, make the final authorisation decision.
Why this does not authorise every CBD product
Novel-food authorisation attaches to a defined ingredient, production process, specification and conditions of use. It is not a general declaration that CBD is safe in any product, at any strength or for any consumer.
The three applications are linked to approximately 3,000 products on the FSA's CBD Public List. That list was created as an interim enforcement measure while applications moved through assessment. Being linked to an application or appearing on the Public List is not the same as holding a final authorisation.
If ministers approve the applications, products relying on them would need to comply with the exact authorised specifications and labelling conditions. Other CBD applications remain subject to their own assessments.
The FSA says it has now published 14 positive safety assessments for CBD novel foods above 97% purity. Each future application will still be considered individually.
Food is not medicine
This decision concerns CBD sold as food, including supplements and, for one application, specified beverages and confectionery. It does not concern prescription cannabis-based medicines.
The distinction is important because the language around CBD frequently blurs the line between food, wellness and treatment.
Existing restrictions on health and medicinal claims continue to apply. The FSA says there are no authorised health claims for CBD foods. A company cannot lawfully convert a novel-food authorisation into evidence that its product treats anxiety, pain, insomnia or any other condition.
A positive safety assessment also answers a narrower question than clinical effectiveness. It evaluates whether a specified ingredient can be consumed safely under proposed conditions. It does not establish that consuming it produces a medical benefit.
The 10 mg limit matters
The FSA's provisional acceptable daily intake remains 10 mg of CBD per day for a healthy adult. The agency describes that as the total daily amount from all food sources, not a target dose or recommendation to consume CBD.
Many products historically marketed in Britain have suggested daily servings above this level. If the first authorisations are granted with the proposed conditions, clearer and more consistent labelling should make that mismatch easier for consumers and enforcement authorities to identify.
The FSA is also maintaining warnings for people who may face greater uncertainty or risk. Anyone taking medication should speak to a healthcare professional before using CBD because it can interact with medicines. People who are pregnant, breastfeeding or trying to conceive are advised not to consume it.
The European Food Safety Authority has taken a more conservative position, setting a provisional safe level of approximately 2 mg per day for a 70 kg adult for certain highly purified CBD products. The two bodies used different datasets and risk-assessment approaches. The disagreement is a reminder that “safe” is always conditional on dose, formulation, population and evidence.
Controlled cannabinoids remain a separate legal issue
CBD itself is not a controlled drug, but products made from cannabis may contain THC and other controlled cannabinoids. Food authorisation does not override the Misuse of Drugs Act or Home Office licensing requirements.
The FSA recommends strict compositional limits, but manufacturers and retailers remain responsible for complying with both food law and controlled-drug law. The agency says additional enforcement guidance is being prepared for local authorities.
That clarity is overdue. For years, consumers have faced a market where the legal status of an ingredient, the status of a finished product and the presence of trace controlled cannabinoids were often discussed as though they were the same question.
What consumers should look for now
Until ministers make a final decision, the position has not changed overnight. Consumers should be wary of any business claiming that the entire UK CBD market has been “approved”.
Product labels should state the amount of CBD clearly enough to understand the daily total. Claims that a food treats a medical condition are a warning sign. So are vague ingredient information, missing batch details and marketing that encourages doses far above the FSA's provisional limit without explaining the regulatory position.
People using prescription medicines should not assume that a supermarket or online CBD product is clinically insignificant simply because it is sold as a supplement. A pharmacist or prescriber can help assess possible interactions.
The editorial view
The CBD market has spent years in regulatory limbo: widely available, heavily marketed and only partly contained by an interim list. Completing the first authorisations would begin replacing that ambiguity with enforceable product specifications and clearer safety information.
That is progress worth recognising. The value lies in the limits, not in a celebratory claim that CBD has been vindicated.
Responsible regulation should make it easier to distinguish a compliant food from an unsubstantiated remedy. It should also make poor labelling and medicinal marketing harder to excuse.
The next test is implementation: timely ministerial decisions, practical guidance for local authorities, visible conditions for consumers and enforcement that does not leave reputable businesses carrying the cost while non-compliant products remain easy to buy.
Key takeaways
- The FSA has recommended the first three high-purity CBD novel-food applications for ministerial authorisation in England and Wales.
- The applications cover defined synthetic CBD and CBD isolates of at least 98% purity; they do not approve every CBD product.
- Ministers will make the final decision. The recommendations are not final authorisations by themselves.
- Proposed conditions include a maximum adult intake of 10 mg per day, strict controlled-cannabinoid specifications and warnings for several higher-risk groups.
- Novel-food authorisation concerns safety under defined conditions. It does not permit medicinal claims or prove that CBD treats a condition.
- CBD businesses must still comply with controlled-drug rules where THC or other controlled cannabinoids are present.
Sources
- CBD novel food applications: recommendations to ministers on first authorisations — Food Standards Agency
- Cannabidiol guidance — Food Standards Agency
- Consumer advice on cannabidiol food products — Food Standards Agency
- CBD Public List — Food Standards Agency
- Cannabis, CBD and other cannabinoids: drug licensing factsheet — Home Office
